You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

allo-Stem Cell Transplantation

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Brain Neuronal Networks, Chemosensory and Trigeminal Functions

Recruiting
  • Hematopoietic Stem Cell Transplantation
    • Oslo, Norway
      University of Oslo
    Aug 21, 2023

    Immune Reconstitution After Allo-HSCT and Blinatumomab

    Not yet recruiting
    • Leukemia, Lymphoid
    • (no location specified)
    Oct 3, 2023

    Allogeneic Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia Trial in Suzhou (VEN+AZA+Modified BUCY)

    Recruiting
    • Allogeneic Hematopoietic Stem Cell Transplantation
    • Acute Lymphoblastic Leukemia
    • VEN+AZA+Modified BUCY
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Apr 10, 2023

    Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Suzhou

    Recruiting
    • Allogeneic Hematopoietic Stem Cell Transplantation
    • +2 more
    • VEN+AZA+Modified BUCY
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Apr 10, 2023

    Donor COVID-19 Infection Status on the Recipient in Allo-HSCT

    Recruiting
    • COVID-19
    • Hematopoietic Stem Cell Transplantation
      • Suzhou, Jiangsu, China
        First Affiliated Hospital of Soochow University
      Jan 10, 2023

      Leukemia, Lymphoid Trial in Chengdu (blinatumomab)

      Recruiting
      • Leukemia, Lymphoid
      • Chengdu, Sichuan, China
        West China Hospital of Sichuan University
      Oct 27, 2023

      Leukemia, Lymphoid Trial in Chengdu (blinatumomab)

      Not yet recruiting
      • Leukemia, Lymphoid
      • Chengdu, Sichuan, China
        West China Hospital of Sichuan University
      Oct 3, 2023

      CNS Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation Trial in Xi'an (TBF regimen, modified BuCY2 regimen)

      Not yet recruiting
      • Central Nervous System Leukemia
      • Allogeneic Hematopoietic Stem Cell Transplantation
      • TBF regimen
      • modified BuCY2 regimen
      • Xi'an, Shaanxi, China
        First Affiliated Hospital of Xi'an Jiaotong University
      Dec 26, 2022

      Hematopoietic Malignancy, Relapse/Recurrence, Hematopoietic Stem Cell Transplantation Trial in Suzhou (Umbilical Cord Blood

      Recruiting
      • Hematopoietic Malignancy
      • +2 more
      • Umbilical Cord Blood Transplantation
      • Suzhou, Jiangsu, China
        The First Affiliated Hospital of Soochow university
      Nov 6, 2023

      CMV Infection, EBV Infection, Stem Cell Transplant Trial (Virus specific T cells)

      Not yet recruiting
      • CMV Infection
      • +2 more
      • Virus specific T cells
      • (no location specified)
      Oct 4, 2023

      T Lymphoblastic Leukemia/Lymphoma Trial in Hangzhou (Chidamide)

      Recruiting
      • T Lymphoblastic Leukemia/Lymphoma
      • Hangzhou, Zhejiang, China
        The First Hospital of Zhejiang Medical Colleage Zhejiang Univers
      Aug 7, 2023

      Acute Myeloid Leukemia Trial (Azacitidine, Donor lymphocyte infusion, Camrelizumab)

      Not yet recruiting
      • Acute Myeloid Leukemia
      • (no location specified)
      Mar 15, 2023

      Acute Myeloid Leukemia Trial in Hefei (RC1012 injection (allo-DNT cells))

      Recruiting
      • Acute Myeloid Leukemia
      • RC1012 injection (allo-DNT cells)
      • Hefei, Anhui, China
        The First Hospital of the University of Science and Technology o
      May 17, 2023

      Leukemia, Myeloid, Acute, MDS, Hematopoietic Stem Cell Transplantation Trial in Shanghai (Venetoclax plus RIC)

      Not yet recruiting
      • Leukemia, Myeloid, Acute
      • +3 more
      • Venetoclax plus RIC
      • Shanghai, Shanghai, China
        Shanghai General Hospital
      Oct 12, 2022

      Relapsed Adult ALL, Relapsed Adult AML Trial in Changchun (Plerixafor)

      Active, not recruiting
      • Relapsed Adult ALL
      • Relapsed Adult AML
      • Changchun, Jilin, China
        First Hospital of Jilin University
      Nov 19, 2023

      Myeloid Malignancies Trial in Chendu (fractionated busulfan-based conditioning regimen)

      Recruiting
      • Myeloid Malignancies
      • fractionated busulfan-based conditioning regimen
      • Chendu, Sichuan, China
        West China Hospital, Sichuan University
      Mar 29, 2023

      Hematopoietic Stem Cell Transplantation Trial in Ann Arbor (Bob's Red Mill®, Starch Placebo)

      Recruiting
      • Hematopoietic Stem Cell Transplantation
      • Bob's Red Mill®
      • Starch Placebo
      • Ann Arbor, Michigan
        University of Michigan Cancer Center
      Dec 20, 2022

      The Gut Microbiome in FLT3- AL Undergoing Allo-HSCT With Or

      Recruiting
      • Acute Leukemia
      • Allogeneic Hematopoietic Stem Cell Transplantation
      • Guangzhou, Guangdong, China
        Department of Hematology,Nanfang Hospital, Southern Medical Univ
      Oct 28, 2022

      Digital Droplet PCR in Early Period After Allo-HSCT to Predict

      Completed
      • Measurable Residual Disease
      • Digital Droplet PCR
      • Hangzhou, Zhejiang, China
        The First Hospital of Zhejiang Medical Colleage Zhejiang Univers
      Aug 17, 2023

      Allo-HSCT as First-line Consolidation in High-risk PTCL

      Recruiting
      • T Cell Lymphoma
        • Beijing, China
          Peking University People's Hospital
        Jul 31, 2022

        Leukemia, Myeloid, Acute Trial in Chengdu (Chidamide)

        Recruiting
        • Leukemia, Myeloid, Acute
        • Chengdu, Sichuan, China
          West China Hospital of Sichuan University
        Dec 27, 2022

        The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or

        Recruiting
        • Acute Myeloid Leukemia With FLT3/ITD Mutation
        • Allogeneic Hematopoietic Stem Cell Transplantation
        • Guangzhou, Guangdong, China
          Department of Hematology,Nanfang Hospital, Southern Medical Univ
        Oct 25, 2022

        Hypomethylating Agent, Venetoclax, Myeloid Malignancy Trial in Shanghai (Venetoclax, Azacitidine or decitabine)

        Recruiting
        • Hypomethylating Agent
        • +2 more
        • Shanghai, Shanghai, China
          Shanghai Jiao Tong University School of Medicine Affilated Shang
        May 2, 2023

        Poor Graft Function Trial (Decitabine, Granulocyte Colony-Stimulating Factor, Thrombopoietin Receptor Agonist)

        Not yet recruiting
        • Poor Graft Function
        • (no location specified)
        Jun 8, 2023

        Hematologic Tumors Trial in France (Allogeneic (Allo) hematopoietic stem cell transplantation)

        Completed
        • Hematologic Neoplasms
        • Allogeneic (Allo) hematopoietic stem cell transplantation
        • Amiens, France
        • +13 more
        Jan 27, 2023